Johnson & Johnson pharma rebrand highlights innovation as a pillar to reinforce trust

Global pharma and medical device giant Johnson & Johnson (J&J) has ditched its iconic cursive logo that dates back to the late 19th century, and rebranded its Janssen pharma division as Johnson & Johnson Innovative Medicine. The move underscores the company’s push to prioritize higher-margin prescription drugs. This strategic move comes amidst a backdrop of significant legal challenges the company has faced in recent years.

In the five-year period from 2018 to 2022, Johnson & Johnson was the most active defendant in medical device and pharmaceutical cases. In addition, before spinning off its consumer health division, the company was targeted in tens of thousands of lawsuits alleging J&J-branded talcum powder causes cancer. Earlier this year, a judge dismissed the company’s attempt to settle thousands of lawsuits through bankruptcy.

The chart below shows the number of cases filed against J&J-affiliated entities in the life sciences secto…

Read more
  • 0

The 50 best-selling pharmaceuticals of 2022: COVID-19 vaccines poised to take a step back

[sizsus/Adobe Stock]

The COVID-19 pandemic has had a profound impact on the best-selling pharmaceuticals, leading to shifts in the list with Pfizer and BioNTech’s Comirnaty surpassing AbbVie’s Humira for the No. 1 spot in 2021. That momentum continued in 2022, with Pfizer and BioNTech jointly raking in $59.1 billion in revenue from the sales of the COVID-19 vaccine. Although Comirnaty maintained its position as the best-selling pharmaceutical of 2022, it experienced a roughly 5% drop in sales compared to the previous year.

As the best-selling pharmaceuticals of 2022 demonstrate, signs are emerging that the reign of COVID-19 vaccines and  other therapies appears to be slipping.. The two companies — and Moderna — plan on hiking prices to address the weakening demand.

Humira: The second best-selling pharmaceutical of 2022 looking strong

Meanwhile, the heavyweight tumor necrosis factor (TNF) block…

Read more
  • 0